'Viagra for the Brain' Slows Alzheimer's Decline by Nearly a Third in Major Trial

AR1001 slowed clinical decline by 31% among a subgroup of people with early Alzheimer's disease, according to topline results reported by its developer, South Korean company AriBio. The experimental drug did not show a statistically significant benefit across the full Phase 3 trial.
AriBio presented findings from the POLARIS-AD trial on 16 November at the Clinical Trials on Alzheimer's Disease conference in Boston. The study involved 1,535 participants.
The company said it plans to discuss the results with the US Food and Drug Administration. AR1001 is taken once daily and is not approved to treat Alzheimer's disease. Alzheimer's is the most common form of dementia, and there is currently no cure.
The AR1001 Trial's Two Different Results
Participants were randomly assigned to receive 30mg of AR1001 or a placebo for 52 weeks. The trial assessed results for all participants and for a prespecified subgroup of 604 people who were not taking other Alzheimer's medicines at the start. These medicines included cholinesterase inhibitors and memantine.
In the subgroup, the difference in decline on the Clinical Dementia Rating-Sum of Boxes scale was 0.44 points. The scale measures thinking and daily functioning. AriBio reported this as a 31% slowing of decline. The result met the trial's threshold for statistical significance, with a p-value of 0.0266, below the 0.03 limit.
Across all participants, the difference was 0.11 points and was not statistically significant, with a p-value of 0.40. The reported 31% slowing applied to the subgroup, not the full trial population.
Adverse events were reported by 69% of participants given AR1001 and 66.4% of those given placebo. Serious events occurred in about 10% of each group.
Treatment was discontinued because of side-effects by 5.2% of participants taking AR1001 and 1.7% taking placebo. Dizziness, diarrhoea and falls were more common among those given AR1001.
How AR1001 Differs From Viagra
AR1001, also known as mirodenafil, is a phosphodiesterase-5 (PDE5) inhibitor, the same drug class as Viagra, whose active ingredient is sildenafil. Mirodenafil was developed for erectile dysfunction. PDE5 inhibitors relax blood vessels, and AriBio is studying whether AR1001 may also affect Alzheimer's disease.
AriBio said AR1001 increased levels of cGMP, a signalling molecule, in spinal fluid. The company also reported lower levels of p-tau217, a marker associated with Alzheimer's, among participants who were not taking other Alzheimer's medicines. The findings are from the company's topline trial results.
If approved, AR1001 would be an oral treatment. Some existing treatments that target amyloid, a protein associated with Alzheimer's, are given by injection or infusion. The trial did not compare AR1001 directly with those treatments.
Why the Subgroup Finding Needs Confirmation
Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, called the results 'an exciting sign' that a new treatment addressing underlying causes of the disease could be on the horizon.
The reported benefit was limited to participants who were not taking other Alzheimer's medicines. The trial did not demonstrate a benefit among those who were, and the overall result was not statistically significant. The subgroup finding requires confirmation in further research.
Dr Sharon Sha of Stanford University, the trial's principal investigator, said the secondary and biomarker findings warranted further evaluation alongside the overall result. AriBio has not announced a date for a regulatory filing. The findings do not show that Viagra or other PDE5 drugs treat Alzheimer's.